Aspects of the breeding biology of Janaira gracilis Moreira & Pires (Crustacea, Isopoda, Asellota)

The biological aspects of incubating females of Janaira gracilis Mbreira & Pires, are described. The marsupium is formed by 4 pairs of oostegites arising from pereopods I-IV. The oostegites appear for the first time at the post-marsupial stage 7 (preparatory stage 1), growing successively at each moult until stage 9 (brooding stage 1), when they reach fully development. The sizes of the eggs increase with the body size of the females. The number of eggs, per female, is a linear function of the body volume, i.e., the fecundity increases with the female's body size. The number of eggs, embryos and juveniles decrease during the marsupial development. This decrease in brood number is higher between the last two marsupial stages, i.e., from stage C to D, than between the preceding marsupial stages. The average and overall brood mortality rate is of 38.95%.São descritos, no presente trabalho, vários aspectos relacionados à biologia de fêmeas grávidas de Janaira gracilis Moreira & Pires. O marsúpio é formado por 4 pares de oostégitos, que partem dos pereópodos I-IV. Os oostégitos, que surgem pela primeira vez no estádio 7 do desenvolvimento pós-marsupial (estágio preparatório 1), crescem nas sucessivas mudas, atingindo no estágio 9 (estágio reprodutor 1) seu pleno desenvolvimento. O tamanho dos ovos é proporcional ao tamanho das fêmeas. O número de ovos, por fêmeas, e proporcional ao volume das fêmeas, isto é, a fecundidade é mais elevada nos exemplares de maior comprimento. O número de ovos, embriões e jovens decresce com o desenvolvimento marsupial, sendo este decréscimo maior entre os dois últimos estágios marsupials (i.é., entre os estágios C e D) do que entre os estágios precedentes. A taxa média de mortalidade marsupial é de 38.95%

Deep sequencing reveals as-yet-undiscovered small RNAs in Escherichia coli

<p>Abstract</p> <p>Background</p> <p>In <it>Escherichia coli</it>, approximately 100 regulatory small RNAs (sRNAs) have been identified experimentally and many more have been predicted by various methods. To provide a comprehensive overview of sRNAs, we analysed the low-molecular-weight RNAs (< 200 nt) of <it>E. coli </it>with deep sequencing, because the regulatory RNAs in bacteria are usually 50-200 nt in length.</p> <p>Results</p> <p>We discovered 229 novel candidate sRNAs (≥ 50 nt) with computational or experimental evidence of transcription initiation. Among them, the expression of seven intergenic sRNAs and three <it>cis</it>-antisense sRNAs was detected by northern blot analysis. Interestingly, five novel sRNAs are expressed from prophage regions and we note that these sRNAs have several specific characteristics. Furthermore, we conducted an evolutionary conservation analysis of the candidate sRNAs and summarised the data among closely related bacterial strains.</p> <p>Conclusions</p> <p>This comprehensive screen for <it>E. coli </it>sRNAs using a deep sequencing approach has shown that many as-yet-undiscovered sRNAs are potentially encoded in the <it>E. coli </it>genome. We constructed the <it>Escherichia coli </it>Small RNA Browser (ECSBrowser; <url>http://rna.iab.keio.ac.jp/</url>), which integrates the data for previously identified sRNAs and the novel sRNAs found in this study.</p

Description de la Carapace des Ostracodes d\u27eau douce de France II. Familie des Cyprididae (genres Cyclocypris, Cypria, Cypricercus, Eucypris)

Volume: 8Start Page: 171End Page: 19

Recurring acute urticaria and abdominal pain: Consider a diagnosis of alpha-galactose anaphylaxis

International audienceFood urticaria is common and generally benign, and it may be of viral or idiopathic aetiology. A food origin of the allergy is frequently sought but rarely found. Mammalian meat anaphylaxis, or alpha-galactose (α-gal) anaphylaxis, is a rare and recently discovered entity

Tacrolimus ointment in the management of atopic keratoconjunctivitis

International audienc

Tacrolimus pommade dans la prise en charge de la kératoconjonctivite atopique

International audienceIntroduction: Atopic keratoconjunctivitis is associated with eyelid eczema. It may require the use of local corticosteroids which if prolonged can be a source of ocular complications. Tacrolimus is an immunosuppressant used in cutaneous application in atopic dermatitis. The aim of this study was to measure the efficacy and tolerance of tacrolimus 0.1% ointment in palpebral application in atopic keratoconjunctivitis.Patients and methods: This retrospective, single-center study was conducted between June 2014 and February 2017. Patients with atopic keratoconjunctivitis not controlled by first-line medical treatments were included. The primary endpoint was the evolution of functional signs as assessed by the NEI-VFQ25 and OSDI quality of life scores. Secondary endpoints were visual acuity and local corticosteroid use.Results: Among the 18 patients included, the mean age was 37.9 ± 16.8 years. The first follow-up visit was on average 68.3 ± 55.3 days after initiation of treatment. The NEI-VFQ25 score was significantly improved for seven of its sub-scores (P Conclusion: Tacrolimus ointment 0.1% in palpebral application appears to be an effective treatment for the management of atopic keratoconjunctivitis.Introduction : la kératoconjonctivite atopique est fréquemment associée à un eczéma palpébral. Elle peut nécessiter le recours aux corticoïdes locaux dont l’utilisation prolongée est source de complications oculaires. Le tacrolimus est un immunosuppresseur, utilisé en application cutanée dans la dermatite atopique. Le but de cette étude est d’évaluer l’efficacité et la tolérance du tacrolimus 0,1 % pommade en application palpébrale dans la kératoconjonctivite atopique.Patients et méthodes : il s’agit d’une étude rétrospective, monocentrique, réalisée entre juin 2014 et février 2017. Les patients présentant une kératoconjonctivite atopique non contrôlée par les traitements médicaux de première intention ont été inclus. Le critère de jugement principal a été l’évolution des signes fonctionnels évaluée par les scores de qualité de vie NEI-VFQ25 et OSDI. Les critères secondaires ont été l’acuité visuelle et la consommation de corticoïdes locaux.Résultats : parmi les 18 patients inclus, l’âge moyen était de 37,9 ± 16,8 ans. La première consultation de contrôle survenait en moyenne 68,3 ± 55,3 jours après l’initiation du traitement. Le score NEI-VFQ25 était amélioré significativement pour sept de ses sous-scores (p Conclusion : le tacrolimus pommade 0,1 % en application palpébrale semble être un traitement efficace dans la prise en charge de la kératoconjonctivite atopique